Echo IQ
Echo IQ is an ASX-listed Australian medical-AI company that develops EchoSolv AS, an FDA-cleared AI clinical decision support platform detecting severe aortic stenosis from routine echocardiographic measurements, sold to US hospital cardiology departments.
- Company typePublic
- Founded2013
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Echo IQ does
Echo IQ is an ASX-listed Australian medical-AI company (ticker EIQ) headquartered in Sydney that develops AI-driven clinical decision support software for structural heart disease detection. The company's core product, EchoSolv AS, is an FDA-cleared platform that applies proprietary algorithms to routine echocardiographic measurements to generate probability scores for severe aortic stenosis, delivering results in seconds at the point of clinical decision without requiring image analysis or EMR integration. The platform was developed using one of the world's largest echocardiographic measurement datasets, comprising more than 200 million measurements, and has been validated through peer-reviewed clinical studies published in JACC Advances and Open Heart.
The company operates a SaaS-based enterprise sales motion targeting cardiology departments and echocardiography labs at major US hospital systems, with strategic deployment partnerships anchored by Mayo Clinic and Mount Sinai (New York). Echo IQ is also advancing EchoSolv HF, a heart failure risk stratification platform currently in research collaboration with Mayo Clinic Arizona for cardio-oncology applications, with an FDA submission planned. The platform addresses a documented 45.7% misclassification rate for severe aortic stenosis by clinicians, with disproportionate impact on women, and delivers a 24.1% reduction in clinical review time.
Commercially, Echo IQ is at an early stage: current revenue is approximately A$0.1M against a market capitalization of approximately A$809.6M, reflecting investor expectations for future US commercial scale rather than current revenue generation. The company is loss-making, employs 11-50 staff, and holds SOC 2 Type II and HIPAA certifications supporting production deployment in US healthcare environments. Management has signaled a H2 revenue ramp pending continued pipeline conversion, with future growth dependent on FDA clearance expansion, reimbursement progress, and scaling beyond its current two named enterprise reference sites.
Echo IQ firmographics
Firmographics- Name
- Echo IQ
- Legal name
- Echo IQ Limited
- Website
- https://echoiq.ai
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Echo IQ is an ASX-listed Australian medical-AI company that develops EchoSolv AS, an FDA-cleared AI clinical decision support platform detecting severe aortic stenosis from routine echocardiographic measurements, sold to US hospital cardiology departments.
- Ownership category
- akta.pro rank
Echo IQ industry classification
Industry- Product category
- AI Clinical Decision Support Software (Cardiac Diagnostics)
- NAICS
- Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)
Keywords
Where Echo IQ is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Echo IQ business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software as a Service (SaaS): Echo IQ generates revenue through software licensing of its EchoSolv AS platform to healthcare institutions. The company is currently pre-revenue with minimal reported revenue (A$0.1M) against a market cap of approximately A$809.6M, indicating early-stage commercial execution with significant growth potential pending regulatory clearance expansion.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free one-month trial available for initial evaluation |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Echo IQ product offering
Product offeringCore offering
Echo IQ develops and sells AI-driven clinical decision support software for structural heart disease detection. Its flagship product, EchoSolv AS, is an FDA-cleared platform that applies proprietary algorithms to routine echocardiographic measurements to produce probability scores for severe aortic stenosis without requiring image analysis. The platform is designed for use by cardiologists and sonographers in hospital cardiology departments and echo labs, delivering results in seconds and reducing clinical review time by 24.1%.
Product overview
Echo IQ develops AI-driven precision diagnostic tools for structural heart disease detection. The company's primary commercial product is EchoSolv AS, an FDA-cleared AI system that applies proprietary algorithms to routine echocardiographic measurements to generate consistent probability scores for severe aortic stenosis. EchoSolv AS is designed to complement clinician review, optimize efficiency and consistency, and support faster clinical review without requiring image analysis or EMR integration.
Differentiator
Problem solved
Functional benefit
Brands
- EchoSolv AS: FDA-cleared AI-powered clinical decision support system for severe aortic stenosis probability assessment using echocardiographic measurements.
- EchoSolv HF
Products and services
- EchoSolv AS FDA-cleared measurement-based AI clinical decision support system that analyzes routine echocardiographic measurements to identify high-probability severe aortic stenosis (sAS) patients. Delivers standardized AS probability scores and guideline-based checks in seconds at the point of clinical decision, without requiring image analysis or EMR integration, for use by cardiologists and cardiac sonographers in hospital cardiology departments and echo labs.
Quantifiable outcome
- 24.1% reduction in clinical review time for echocardiographic studies
- +3 more outcomes
Companies that use Echo IQ
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Echo IQ technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Echo IQ partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Mayo ClinicflagshipEcho IQ has established a strategic partnership with Mayo Clinic for clinical validation and deployment of its EchoSolv platform. The partnership involves clinical validation work and has resulted in EchoSolv being deployed at Mount Sinai in New York through this collaboration. Mayo Clinic serves as a key validation partner for FDA clearance and reimbursement progress, with the relationship extending to research collaborations including cardiac risk stratification in oncology patients.
- Mount SinaicoreMount Sinai in New York serves as a deployment partner for Echo IQ's EchoSolv AS platform through the Mayo Clinic partnership. This represents the company's initial commercial deployment site in the US market, positioning Mount Sinai as a flagship reference customer for the cardiac AI technology.
- Mayo Clinic ArizonacoreResearch collaboration with Mayo Clinic Arizona to evaluate Echo IQ's AI platform for cardiac risk stratification in oncology patients undergoing cancer therapy. Study to be conducted under Dr. Chadi Ayoub, assessing predictive heart failure risk scores using routinely acquired echocardiographic data. Results expected first half of 2027, with intent to co-author peer-reviewed manuscript upon completion.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Echo IQ competitors and assessment
Company assessmentDirect peers
- HeartFlow: HeartFlow is a cardiac AI company whose FFRct analysis non-invasively assesses coronary artery disease from CT imaging. Echo IQ's US President Nick Lubbers previously drove FFRct adoption at HeartFlow, and both companies apply AI decision support to routine cardiac imaging data in the hospital cardiology workflow.
- Ultromics: Ultromics is an AI echocardiography company focused on structural heart disease and heart failure detection. It is a direct functional competitor to EchoSolv AS, applying AI to echo data to help clinicians diagnose and risk-stratify cardiac conditions.
Emerging players
- iRhythm Technologies: iRhythm applies AI to ambulatory cardiac monitoring (Zio patch) for arrhythmia detection. While focused on rhythm rather than structural heart disease, it is a cardiac AI platform selling into the same cardiology department buyers and has overlapping US commercial relationships.
- Tempus AI: Tempus AI is a precision medicine AI company that built out a cardiology division led by Echo IQ's US President Nick Lubbers. It sells AI-enabled clinical decision support into health systems and overlaps with Echo IQ on the AI-driven cardiology workflow.
- CureMetrix: CureMetrix is an AI medical imaging company focused on breast cancer detection, where Echo IQ's CTO Sam Dribin was previously CTO for nine years. It is a comparable specialty AI imaging startup with FDA-cleared products and a similar clinical AI commercialization journey.
- Acarix: Acarix develops AI-based acoustic and ECG analysis for coronary artery disease detection. Echo IQ board member Ken Nelson sits on Acarix's board, and both companies target AI-driven, non-invasive cardiac diagnostic decision support in similar hospital workflows.
- HeartBeam: HeartBeam is a cardiac diagnostic technology company developing AI-enabled ECG-based detection. Echo IQ board member Ken Nelson also serves on HeartBeam's board, and both companies are early-stage cardiac AI diagnostic platforms pursuing FDA pathways.
Broad incumbents
- BioTelemetry (Philips): BioTelemetry, now part of Philips, is a leading cardiac monitoring and digital health company. Echo IQ board member Ken Nelson led commercialization there, and BioTelemetry represents the incumbent cardiac digital health category that Echo IQ's AI decision support must sell alongside.
- GE HealthCare: GE HealthCare is a leading manufacturer of echocardiography systems and a major incumbent in cardiac imaging. Echo IQ's measurement-based AI decision support sits on top of echo machines like GE's and must compete with or be integrated alongside vendor-native AI features.
- Philips (Cardiac Care): Philips is a major vendor in echocardiography and cardiac monitoring (including through BioTelemetry) and a broad incumbent in hospital AI imaging. Its installed base and bundled AI capabilities represent the principal competitive context for EchoSolv AS adoption.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Echo IQ social profiles
Digital presenceEcho IQ compliance and trust
Trust signalCompliance2 records
Echo IQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
Echo IQ leadership team
Management profileNumber of profiles
Profiles11 records
Echo IQ funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Echo IQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Echo IQ
What does Echo IQ do?
Echo IQ develops and sells AI-driven clinical decision support software for structural heart disease detection. Its flagship product, EchoSolv AS, is an FDA-cleared platform that applies proprietary algorithms to routine echocardiographic measurements to produce probability scores for severe aortic stenosis without requiring image analysis. The platform is designed for use by cardiologists and sonographers in hospital cardiology departments and echo labs, delivering results in seconds and reducing clinical review time by 24.1%.
Is Echo IQ a public or private company?
Echo IQ is a public company. It is classified as public and is currently operating.
When was Echo IQ founded?
Echo IQ was founded in 2013. It employs 11 to 50 people.
Where is Echo IQ based?
Echo IQ is headquartered in Sydney, Australia, in the Oceania region.
How does Echo IQ make money?
One revenue line is on record: software as a Service (SaaS).
Who are Echo IQ's main competitors?
Direct peers on record are HeartFlow and Ultromics. Emerging players are iRhythm Technologies, Tempus AI, CureMetrix, Acarix and HeartBeam. Broad incumbents are BioTelemetry (Philips), GE HealthCare and Philips (Cardiac Care).
Does Echo IQ have an API?
No public API is recorded for Echo IQ.
What industry is Echo IQ in?
Echo IQ's product category is AI Clinical Decision Support Software (Cardiac Diagnostics). Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 541511 and its SIC code is 7370.